当前位置: X-MOL 学术Lancet Neurol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Cenobamate: new hope for treatment-resistant epilepsy.
The Lancet Neurology ( IF 48.0 ) Pub Date : 2019-11-14 , DOI: 10.1016/s1474-4422(19)30434-x
Stephan Arnold 1
Affiliation  

A third of patients with epilepsy worldwide are in need of more effective anticonvulsive drugs, since their epileptic seizures remain uncontrolled with currently available medical treatments. To date, despite that a dozen new drugs have been developed in the past 20 years, the chance of complete seizure control after failure of two anticonvulsant treatments, even in patients with newly diagnosed epilepsy, is low. In The Lancet Neurology, Gregory Krauss and colleagues report results of the second phase 2 double-blind, randomised, placebo-controlled, dose-response trial on the safety and efficacy of adjunctive cenobamate (YKP3089) for the treatment of focal epilepsy. The mechanism of action of this drug is still under investigation. Beside inhibiting excitatory sodium-channel currents, it is believed that cenobamate enhances inhibition by modulation of GABAA receptors.

中文翻译:

烯草酸酯:抗癫痫药的新希望。

全世界有三分之一的癫痫患者需要更有效的抗惊厥药,因为目前可用的药物治疗无法控制他们的癫痫发作。迄今为止,尽管在过去的20年中已经开发了十几种新药,但是即使在刚诊断出癫痫病的患者中,两种抗惊厥药治疗失败后,完全控制癫痫发作的机会仍然很低。在《柳叶刀》神经病学中,格雷戈里·克劳斯(Gregory Krauss)及其同事报告了第二期2次双盲,随机,安慰剂对照,剂量反应试验的结果,该试验涉及了联合醋巴氨基酸酯(YKP3089)治疗局灶性癫痫的安全性和有效性。该药物的作用机理仍在研究中。除了抑制兴奋性钠通道电流外,据信cenobamate还可以通过调节GABAA受体来增强抑制作用。
更新日期:2019-12-13
down
wechat
bug